Cooper Companies, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
The Cooper Companies reported an 8% revenue increase to $1.08 billion but swung to a net loss due to a $271.6 million litigation accrual related to a surgical product recall.
NASDAQ
The Cooper Companies, Inc. reported a significant increase in net income and diluted EPS for the first quarter of fiscal 2026, driven by strong performance across both CooperVision and CooperSurgical segments.
NASDAQ
The Cooper Companies reported mixed third-quarter results with strong CooperVision sales growth offset by a significant operating loss in CooperSurgical due to product line write-offs.
NASDAQ
The Cooper Companies, Inc. reported increased net sales and operating income for the second quarter and first six months of fiscal 2025, driven by strong performance in both CooperVision and CooperSurgical segments, despite a material weakness in internal controls and a higher effective tax rate impacting quarterly net income.
NASDAQ
The Cooper Companies' Q1 2025 results show increased revenue and operating income, driven by growth in CooperVision and CooperSurgical, despite unfavorable foreign exchange impacts and a previously identified material weakness in IT controls.
NASDAQ
10-Q: Cooper Companies Reports Strong Q3 2024 Results Driven by Sales Growth and Strategic Acquisitions
The Cooper Companies reported a solid third quarter for fiscal year 2024, with increased net sales and operating income across both its CooperVision and CooperSurgical segments.
NASDAQ
The Cooper Companies reported a significant increase in net income and sales for the second quarter of 2024, driven by growth in both its CooperVision and CooperSurgical segments.
NASDAQ
The Cooper Companies reported a slight decrease in net income for the first quarter of 2024, despite increased sales, driven by acquisition costs and changes in tax rates.